Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HEXA | P06865 | 1/20 | 0.31 |
| ▸ | HEXB | P07686 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17599200 | 0.94 | HEXA (0.33) | HEXAHEXB | |
| SCHEMBL17599193 | 0.88 | — | — | |
| SCHEMBL17599188 | 0.83 | — | — | |
| SCHEMBL17599182 | 0.83 | TSHR (0.34) | — | |
| SCHEMBL17599206 | 0.82 | — | — | |
| SCHEMBL8516521 | 0.81 | MGLL (0.39) | — | |
| SCHEMBL17599186 | 0.81 | KMT2A (0.36) | — | |
| SCHEMBL17599190 | 0.81 | — | — | |
| SCHEMBL17599184 | 0.78 | KMT2A (0.39) | — | |
| SCHEMBL17599195 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2998327-B1 | POLYOLEFIN MODIFIED WITH NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND ADHESIVE COMPOSITION CONTAINING SAME | TOYO BOSEKI (JP) | 2022-03-23 | — | — | EP | disclosed |
| US-10253114-B2 | Polyolefin modified with nitrogen-containing heterocyclic compound, and adhesive composition containing same | TOYOBO CO., LTD. (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20160130373-A1 | POLYOLEFIN MODIFIED WITH NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND ADHESIVE COMPOSITION CONTAINING SAME | TOYOBO CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| EP-2998327-A1 | POLYOLEFIN MODIFIED WITH NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND ADHESIVE COMPOSITION CONTAINING SAME | TOYOBO CO., LTD. (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-20110201608-A1 | SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-18 | — | — | US | disclosed |
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1255752-B1 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2007-01-11 | — | — | US | disclosed |
| US-7125905-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040186161-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040063773-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2004-04-01 | — | — | US | disclosed |
| US-20030216410-A1 | Combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2003-11-20 | — | — | US | disclosed |
| US-6573293-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. | 2003-06-03 | — | — | US | disclosed |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN. INC. | 2003-05-29 | — | — | US | disclosed |
| EP-1255752-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PHARMACIA & UPJOHN COMPANY LLC | 2002-10-24 | — | — | US | disclosed |
| WO-2002081466-A1 | PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES | SUGEN, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001060814-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216410-A1 | Combination therapy for the treatment of cancer | PTGS2, PTGES2, PTGFR | HEXA 2626/4885HEXB 3010/4885HTR2A 1367/4885 |
| US-20040186161-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | HEXA 3564/4885HEXB 3913/4885HTR2A 1651/4885 |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | HEXA 3564/4885HEXB 3913/4885HTR2A 1651/4885 |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, PLK2, PNCK | HEXA 4709/4885HEXB 4746/4885HTR2A 2834/4885 |
| US-20110201608-A1 | SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES | NR4A1, NR4A3, NR0B1 | HEXA 3759/4885HEXB 3106/4885HTR2A 794/4885 |
| US-20040063773-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | HEXA 4741/4885HEXB 4768/4885HTR2A 2570/4885 |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | MAP3K15, MAP3K20, MAP3K19 | HEXA 1406/4885HEXB 2093/4885HTR2A 769/4885 |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | HEXA 4741/4885HEXB 4768/4885HTR2A 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.